Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2014 Nov 17;3(6):e001363.
doi: 10.1161/JAHA.114.001363.

Effects of cinacalcet on atherosclerotic and nonatherosclerotic cardiovascular events in patients receiving hemodialysis: the EValuation Of Cinacalcet HCl Therapy to Lower CardioVascular Events (EVOLVE) trial

David C Wheeler  1 , Gerard M London  2 , Patrick S Parfrey  3 , Geoffrey A Block  4 , Ricardo Correa-Rotter  5 , Bastian Dehmel  6 , Tilman B Drüeke  7 , Jürgen Floege  8 , Yumi Kubo  6 , Kenneth W Mahaffey  9 , William G Goodman  6 , Sharon M Moe  10 , Marie-Louise Trotman  6 , Safa Abdalla  9 , Glenn M Chertow  9 , Charles A Herzog  11 ; EValuation Of Cinacalcet HCl Therapy to Lower CardioVascular Events (EVOLVE) Trial Investigators
Affiliations
Randomized Controlled Trial

Effects of cinacalcet on atherosclerotic and nonatherosclerotic cardiovascular events in patients receiving hemodialysis: the EValuation Of Cinacalcet HCl Therapy to Lower CardioVascular Events (EVOLVE) trial

David C Wheeler et al. J Am Heart Assoc. .

Erratum in

  • J Am Heart Assoc. 2015 Jan;4(1):e000570

Abstract

Background: Premature cardiovascular disease limits the duration and quality of life on long-term hemodialysis. The objective of this study was to define the frequency of fatal and nonfatal cardiovascular events attributable to atherosclerotic and nonatherosclerotic mechanisms, risk factors for these events, and the effects of cinacalcet, using adjudicated data collected during the EValuation of Cinacalcet HCl Therapy to Lower CardioVascular Events (EVOLVE) Trial.

Methods and results: EVOLVE was a randomized, double-blind, placebo-controlled clinical trial that randomized 3883 hemodialysis patients with moderate to severe secondary hyperparathyroidism to cinacalcet or matched placebo for up to 64 months. For this post hoc analysis, the outcome measure was fatal and nonfatal cardiovascular events reflecting atherosclerotic and nonatherosclerotic cardiovascular diseases. During the trial, 1518 patients experienced an adjudicated cardiovascular event, including 958 attributable to nonatherosclerotic disease. Of 1421 deaths during the trial, 768 (54%) were due to cardiovascular disease. Sudden death was the most frequent fatal cardiovascular event, accounting for 24.5% of overall mortality. Combining fatal and nonfatal cardiovascular events, randomization to cinacalcet reduced the rates of sudden death and heart failure. Patients randomized to cinacalcet experienced fewer nonatherosclerotic cardiovascular events (adjusted relative hazard 0.84, 95% CI 0.74 to 0.96), while the effect of cinacalcet on atherosclerotic events did not reach statistical significance.

Conclusions: Accepting the limitations of post hoc analysis, any benefits of cinacalcet on cardiovascular disease in the context of hemodialysis may result from attenuation of nonatherosclerotic processes.

Clinical trials registration: Unique identifier: NCT00345839. URL: ClinicalTrials.gov.

Keywords: atherosclerosis; cardiovascular diseases; heart failure; kidney; sudden death.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Adjudicated causes of death in the EVOLVE study population. CV indicates cardiovascular; EVOLVE, EValuation Of Cinacalcet HCl Therapy to Lower CardioVascular Events.
Figure 2.
Figure 2.
Cumulative incidence function plots, intention‐to‐treat analysis, of (A) nonatherosclerotic events, (B) atherosclerotic events, (C) heart failure, and (D) sudden death.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. U.S. Renal Data System. USRDS 2012 Annual Data Report: Atlas of Chronic Kidney Disease and End‐Stage Renal Disease in the United States. 2012Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases
    1. Cheung AK, Sarnak MJ, Yan G, Berkoben M, Heyka R, Kaufman A, Lewis J, Rocco M, Toto R, Windus D, Ornt D, Levey AS. Cardiac diseases in maintenance hemodialysis patients: results of the HEMO study. Kidney Int. 2004; 65:2380-2389. - PubMed
    1. Wanner C, Krane V, Marz W, Olschewski M, Mann JF, Ruf G, Ritz E. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005; 353:238-248. - PubMed
    1. Weiner DE, Tighiouart H, Elsayed EF, Griffith JL, Salem DN, Levey AS, Sarnak MJ. The Framingham predictive instrument in chronic kidney disease. J Am Coll Cardiol. 2007; 50:217-224. - PubMed
    1. Wheeler DC, Haynes R, Landray MJ, Baigent C. In: Taal MW, Chertow GM, Marsden P, Skorecki K, Yu ASL, Brenner BM. (eds.). Cardiovascular aspects of kidney disease. Brenner and Rector's The Kidney. 20129th edPhiladelphia, PA: Elsevier Saunders; 2059-2080.

Publication types

MeSH terms

Associated data